Short Communication

RFP Gastroenterology International
Volume 8 Number 1, January - June 2023

Need of Understanding: AVH takes more than a 45 Days

Satender Tanwar[1], Mayank Chugh[2]

How to cite this article:
Satender Tanwar, Mayank Chugh/Need of Understanding: AVH takes more than a 45 Days/RFP Gastroenterology International. 2023;8(1):33-35.

Abstract

Viral hepatitis, caused by hepatitis viruses A through E, still remains a major public health problem in India. AVH being most commonly encountered disease and the times it get takes for the recovery is quite questionable. The patient or parents of the child usually changes the doctors as and when there is change in the laboratory parameters. The phase of the hepatitis is divided in to the three phase where the early phase, mid phase and recovery phase. The early phase where the symptomatically patient has the high raise in the LFT parameter such as the SGOT and SGPT. The second phase where the transaminase starts settling down and the bilirubin starts increasing and transaminase starts settling down and later phase where the Bilirubin stay high and starts falling down and transaminase touches he baseline, overall procedure takes the 30-45 days for recovery in the patients. This study has been made to understand the pathophysiology of the acute viral hepatitis and its recovery takes the quite prolonged. The concept and the different phases of the acute viral hepatitis has been mentioned base on the textual and the clinical experience of the gastroenterologist.

Keywords: Acute phase; AVH, Bilirubin, Jaundice; Vomiting; Pain Abdomen; Recovery phase; Transaminases; Vaccination.

Author Affiliation: [1,2]Consulting Gastroenterologist & Hepatologist, Department of General Medicine and Gastroenterology, Chugh Hospital, Bhiwani 127021, Haryana, India.

Corresponding Author: Mayank Chugh, Consulting Gastroenterologist & Hepatologist, Department of General Medicine and Gastroenterology, Chugh Hospital, Bhiwani 127021, Haryana, India.

E-mail: chughmayank@gmail.com

Received on: 17.07.2023

Accepted on: 30.08.2023

INTRODUCTION

Viral hepatitis, caused by hepatitis viruses A through E, still remains a major public health problem in India. Hepatic disease have found to burden the society in all age groups.[1] No age group is spare of these ailments varies from acute to chronic and mild to fulminant in Nature. The Child age groups is the most tender one and maximally effected the children at various age groups in the present study the children, effected found to have history of fever with persisting vomiting and pain

abdomen on evaluation found to have the Hepatitis A on laboratory investigation.[2]

Phases of the Acute Hepatitis:

Acute Phase	Middle Phase	Recovery Phase
0-5 Days	7 Days – 21 Days	More Than 21 Days – 45 Days
Transaminase	Bilirubin Starts Increasing and Reaches Peak	Transaminase Settles to Base Line and Peaked Bilirubin Starts Settling Down.
Raises Markedly Reaches Peak	Bilirubin Reaches Maximum Upto 20MG/DL	Tranasminase Comes Below 100 IU/L. and More than 30 Days – 45 Days Bilirubin comes to base line in different cases Varies.

Bilirubin is the product of heme metabolism, especially of hemoglobin resulting from the senescent erythrocytes (80–85%); the remainder fraction comes from inefficient hematopoiesis and other hemo-containing proteins (myoglobin, cytochromes, and peroxidase). The resulting heme, composed of a molecule of protoporphyrin IX and a $Fe2^{+}$ ion, is degraded by the hemo-oxygenase enzyme into a linear molecule of four pyrrolic rings called biliverdin.[3] Free iron ($Fe3^{+}$) and carbon monoxide are also released. Then, biliverdin is converted by the enzyme biliverdin reductase into bilirubin. The major product is the ring-shaped IXα isoform, which is hydrophobic.[4] Bilirubin binding to albumin (Kd ≈ 10−7–10−8 mol/L) prevents isomerization and enables its transportation through the body into the liver.[5]

Albumin bound bilirubin enters the liver through the sinusoids. Organic anion transporting polypeptides (OATP) 1B1 and 1B3, encoded in the solute carrier organic anion (SLCO) gene superfamily, mediate bilirubin uptake into the hepatocyte.[6] Once inside liver cells, bilirubin binds water soluble proteins known as ligandins or Y proteins, which are cytosolic proteins of the glutathione S-transferase family that delay the efflux of internalized bilirubin.[7] Then, in the smooth endoplasmic reticulum, bilirubin is conjugated with glucuronic acid by UDPGT-1A1 to form bilirubin glucuronides.[8] Bilirubin glucuronide returns to cytosol, from which it is transported across the canalicular membrane for excretion into bile, or across the sinusoidal membrane for secretion into plasma, where it undergoes reuptake by the same OATP1B1/3 transporters.[9] In the canalicular membrane, the process is mediated by an ATP-dependent apical transporter, ATP-binding cassette-C2 (ABCC2), formerly known as MRP2–multidrug related protein-2.[10]

Bilirubin is part of the basic study of liver function. There are numerous measurement platforms and methods, being the diazo method the gold standard. The sample most commonly used is serum or plasma, and also urine, for which optimal pre-analytical conditions are required. Despite its limited sensitivity and specificity, bilirubin is frequently measured for the evaluation of different pathologies related to liver and bile function.[11] Total and conjugated bilirubin concentrations provide guidance about the origin of the alteration. The same occurs with bilirubin and urobilinogen determination in serum and urine. In the hospital context, bilirubin concentrations are very useful for prognosis of acute liver disease and monitoring chronic liver disease. These results must be interpreted in the context of patient anamnesis, degree of alteration, and other clinical laboratory parameters.[12]

CONCLUSION

In Viral hepatitis, most of the time self limiting but takes 45 days to recover because it binds with the albumin which has half life of 28 days and reason being once it binds has to process till the albumin get washed of from the body.

REFERENCES

1. Alberts CJ, Boyd A, Bruisten SM, Heijman T, Hogewoning A, Rooijen MV, Siedenburg E, Sonder GJB. Hepatitis A incidence, seroprevalence, and vaccination decision among MSM in Amsterdam, the Netherlands. Vaccine. 2019 May 09;37(21):2849-2856.
2. Johnson KD, Lu X, Zhang D. Adherence to hepatitis A and hepatitis B multi-dose vaccination schedules among adults in the United Kingdom: a retrospective cohort study. BMC Public Health. 2019 Apr 15;19(1):404.
3. Brennan J, Moore K, Sizemore L, Mathieson SA, Wester C, Dunn JR, Schaffner W, Jones TF. Notes

from the Field: Acute Hepatitis A Virus Infection Among Previously Vaccinated Persons with HIV Infection - Tennessee, 2018. MMWR Morb Mortal Wkly Rep. 2019 Apr 12;68(14):328-329.

4. Wilson E, Hofmeister MG, McBee S, Briscoe J, Thomasson E, Olaisen RH, Augustine R, Duncan E, Bamrah Morris S, Haddy L. Notes from the Field: Hepatitis A Outbreak Associated with Drug Use and Homelessness - West Virginia, 2018. MMWR Morb Mortal Wkly Rep. 2019 Apr 12;68(14):330-331.
5. Tan EM, Marcelin JR, Virk A. Pre-travel counseling for immunocompromised travelers: A 12-year single-center retrospective review. Infect Dis Health. 2019 Feb;24(1):13-22.
6. Nelson NP, Link-Gelles R, Hofmeister MG, Romero JR, Moore KL, Ward JW, Schillie SF. Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel. MMWR Morb Mortal Wkly Rep. 2018 Nov 02;67(43):1216-1220.
7. Gervasi G, Biticchi M, Zaratti L, Franco E. [Epidemics of Hepatitis A and opportunities for vaccination: a focus on the category of men who practice sex with men (MSM)]. IgSanitaPubbl. 2018 May-Jun;74(3):295-304.
8. Waszczuk K, Waszczuk E, Szenborn L. Can we better protect patients with inflammatory bowel disease against infections - patient attitude and personal immunization knowledge. ActaGastroenterol Belg. 2018 Apr-Jun;81(2):257-261.
9. O'Leary ST, Kimberlin DW. Update From the Advisory Committee on Immunization Practices. J Pediatric Infect Dis Soc. 2018 Aug 17;7(3):181-187.
10. Singh V, Crosby RA, Gratzer B, Gorbach PM, Markowitz LE, Meites E. Disclosure of Sexual Behavior Is Significantly Associated With Receiving a Panel of Health Care Services Recommended for Men Who Have Sex With Men. Sex Transm Dis. 2018 Dec;45(12):803-807.
11. Doshani M, Weng M, Moore KL, Romero JR, Nelson NP. Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Persons Experiencing Homelessness. MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):153-156.
12. Tajammal R, Ali IA, Syed T, Nusrat S. Immunization Against Hepatitis A Virus and Hepatitis B Virus in Patients with Chronic Liver Disease: Are We Doing a Good Job? Cureus. 2018 Apr 24;10(4):e2528.